Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 3.2% – Here’s What Happened

Tiziana Life Sciences Ltd (NASDAQ:TLSA)’s stock price dropped 3.2% during trading on Monday . The stock traded as low as $1.5103 and last traded at $1.53. 113,997 shares traded hands during mid-day trading, a decline of 30% from the average daily volume of 163,390 shares. The stock had previously closed at $1.58.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on TLSA. Wall Street Zen downgraded Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings upgraded Tiziana Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Tiziana Life Sciences Stock Down 3.2%

The firm’s 50 day moving average price is $1.31 and its two-hundred day moving average price is $1.50.

Tiziana Life Sciences (NASDAQ:TLSA) last released its quarterly earnings results on Friday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter.

Institutional Trading of Tiziana Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Zhang Financial LLC lifted its stake in shares of Tiziana Life Sciences by 12.0% in the first quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock worth $131,000 after acquiring an additional 12,000 shares in the last quarter. Marshall Wace LLP grew its stake in Tiziana Life Sciences by 5.2% during the 4th quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock valued at $420,000 after purchasing an additional 14,005 shares in the last quarter. Rachor Investment Advisory Services LLC acquired a new stake in Tiziana Life Sciences during the 4th quarter valued at approximately $25,000. Cubist Systematic Strategies LLC purchased a new stake in Tiziana Life Sciences during the 1st quarter worth approximately $25,000. Finally, HRT Financial LP purchased a new stake in Tiziana Life Sciences during the 4th quarter worth approximately $36,000.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.